Swiss offer Geneva space for WHO pathogen exchange
WHO director general Tedros Ghebreyesus thanked Switzerland for offering a secure lab in Geneva.
Keystone / Martial Trezzini
Switzerland has offered secure space for the Geneva-based WHO to store pathogen materials as part of a proposed new global mechanism for sharing pathogens in the fight against Covid-19.
This content was published on
2 minutes
Keystone-SDA/Reuters/jc
“The pandemic has shown that there is an urgent need for a globally agreed system for sharing pathogen materials and clinical samples, to facilitate the rapid development of medical countermeasures as global public goods,” World Health Organization director-general Tedros Ghebreyesus said on Friday.
Speaking in closing remarks to a virtual WHO Assembly, he stressed this was needed quickly.
The WHO is proposing “a new approach that would include a repository for materials housed by WHO in a secure Swiss facility; an agreement that sharing materials into this repository is voluntary; that WHO can facilitate the transfer and use of the materials; and a set of criteria under which WHO would distribute them”.
Ghebreyesus said a number of countries had shown interest. He thanked Swiss health minister Alain Berset and the federal government “for offering a BSL 4 lab to support this initiative”.
COVAX on track
Meanwhile, the COVAX vaccine pool led by WHO and the Gavi Vaccine Alliance said on Friday it has exceeded its interim target of raising more than $2 billion (CHF1.83 billion) to buy and distribute Covid-19 vaccines for poorer countries.
These funds will allow COVAX to buy an initial one billion vaccine doses for 92 eligible countries that would not otherwise be able to afford them, according to a Gavi statement. But it said a further $5 billion will be needed in 2021 to buy Covid-19 vaccine doses as they come through development and are approved by regulators.
Gavi chief Seth Berkley also told journalists on Friday that US drugmaker Pfizer and its partner BioNTech, who this week said their Covid-19 vaccine was 90% effective in initial trials, had expressed interest in supplying doses to COVAX.
Popular Stories
More
Swiss Politics
Why cars still reign supreme in ‘rail-nation’ Switzerland
Swiss central banker wants to boost equity to head off risks
This content was published on
Equity levels at the Swiss National Bank (SNB) are much too low for the risks its large balance sheet poses, according to Martin Schlegel.
Beer sales in Switzerland watered down by bad weather
This content was published on
The past brewing year fell through in Switzerland, partly due to the bad weather. Beer sales shrank again. For the first time, per capita consumption fell below the 50 liter mark.
Compensation for Syrian after pregnant wife denied help on Swiss train
This content was published on
Switzerland’s Federal Court has partially upheld the appeal of a Syrian family being deported from Switzerland to Italy in 2014. The man now also receives compensation.
Swiss-EU negotiations: Cassis to meet Sefcovic in Bern
This content was published on
Swiss Foreign Minister Ignazio Cassis will meet the Vice-President of the EU Commission, Maros Sefcovic, in Bern on Wednesday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Why Swiss participation in WHO’s Covid-19 vaccine plan matters
This content was published on
As the second coronavirus wave makes finding vaccines even more urgent, we look at Swiss participation in the WHO's vaccine pool.
This content was published on
Switzerland confirms participation in WHO COVAX initiative aimed at ensuring equitable access to Covid-19 vaccines when they are approved.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.